Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic

Status Completed

Clinical Trial Summary

The purpose of this study is to determine whether BNP7787 is effective in preventing or reducing neurotoxicity (nerve damage) caused by paclitaxel (Taxol®).

Clinical Trial Description

Chemotherapy induced toxicities are common and serious problems for many patients who receive treatment for cancer. Chemotherapy induced toxicities can adversely impact the quality of life and the ability of patients to continue treatment for their cancer. One such toxicity associated with the use of paclitaxel (Taxol®) is peripheral neurotoxicity. Paclitaxel is an active drug in the treatment of metastatic breast cancer as first-line treatment and in patients with recurrent or refractory disease, including patients who have failed to respond to previous anthracycline therapy. Recent studies with paclitaxel using a weekly schedule of administration have demonstrated higher tumor response rates and disease free survival accompanied by a shift in the frequency of certain toxicities, increased dose intensity and a potential means to improve the treatment schedule of paclitaxel for improved patient benefit. Paclitaxel induced neurotoxicity remains an important problem that limits the ability to improve the schedule of administration of this drug. To date, there is no effective or FDA approved therapy to prevent the development of or reduce the frequency or severity of paclitaxel-induced neurotoxicity. BNP7787 is an investigational new drug that is undergoing development for chemoprotection of platinum and taxane associated common clinical toxicities, particularly the prevention of chemotherapy-induced neurotoxicity. In this Phase 3 clinical trial the safety and effectiveness of BNP7787 in preventing or mitigating the frequency, severity, worsening of grade, time to onset, duration and discontinuation of therapy due to paclitaxel-induced neurotoxicity will be assessed in patients with metastatic breast cancer. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00039780
Study type	Interventional
Source	BioNumerik Pharmaceuticals, Inc.
Contact
Status	Completed
Phase	Phase 3
Start date	September 2001
Completion date	September 2014

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT05558917` - Comparison Between PECS BLOCK 2 vs ESP BLOCK in Ocnologic Breast Surgery	N/A
Active, not recruiting	`NCT03664778` - Abbreviated Breast MRI After Cancer Treatment
Recruiting	`NCT03144622` - 18F-FSPG PET/CT Imaging in Patients With Cancers
Completed	`NCT05452499` - Pain Neuroscience Education and Therapeutic Exercise as a Treatment for Breast Cancer Survivors Living With Sequelae	N/A
Active, not recruiting	`NCT04568902` - Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer	Phase 1
Completed	`NCT02860585` - Evaluation of Survival in Patients With Metastatic Breast Cancer Receiving High-dose Chemotherapy With Autologous Haematopoietic Stem Cell Transplantation	N/A
Completed	`NCT04059809` - Photobiomodulation for Breast Cancer Radiodermatitis	Phase 2/Phase 3
Recruiting	`NCT04557449` - Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors	Phase 1/Phase 2
Completed	`NCT03698942` - Delphinus SoftVue™ ROC Reader Study
Completed	`NCT00092950` - Exercise in Women at Risk for Breast Cancer	Phase 2
Terminated	`NCT04123704` - Sitravatinib in Metastatic Breast Cancer	Phase 2
Not yet recruiting	`NCT02151071` - The Breast Surgery EnLight and LightPath Imaging System Study	Phase 1/Phase 2
Recruiting	`NCT02934360` - TR(ACE) Assay Clinical Specimen Study	N/A
Active, not recruiting	`NCT02950064` - A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations	Phase 1
Not yet recruiting	`NCT02876848` - A Novel E-Health Approach in Optimizing Treatment for Seniors (OPTIMUM Study)	N/A
Completed	`NCT02931552` - Nuevo Amanecer II: Translating a Stress Management Program for Latinas	N/A
Recruiting	`NCT02547545` - Breast Cancer Chemotherapy Risk Prediction Mathematical Model	N/A
Completed	`NCT02652975` - Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium	N/A
Completed	`NCT02518477` - Preventive Intervention Against Lymphedema After Breast Cancer Surgery	N/A
Completed	`NCT02303366` - Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms